Company aims to develop a model for delivering psychedelic-assisted therapy.
Compass Pathways said Jan. 16 it entered into a research collaboration agreement with Hackensack Meridian Health, a step that will help the company establish a framework for delivering psychedelic-assisted therapy.
“Our collaboration with Hackensack Meridian Health will help us understand how investigational COMP360 psilocybin treatment, if approved, could be delivered to patients and represents another important milestone in our mission to provide better treatment options for people who urgently need them,” said Kabir Nath, CEO of Compass Pathways.
Compass is currently seeking U.S. Food and Drug Administration approval for its investigational COMP360 psilocybin treatment.
The agreement with HMH is pending FDA approval of COMP360, Compass said.
The partnership will help Compass understand the challenges and opportunities of delivering care to those living with depression, to inform how future clinical trials of COMP360 psilocybin treatment are designed and to understand how it will be delivered to patients, Compass said.
COMP360 is Compass’s investigational proprietary formulation of synthetic psilocybin, administered in conjunction with psychological support.
Hackensack Meridian Health has a network of 18 hospitals and more than 500 patient care locations.